Biote Announces Definitive Settlement with Founder Company to repurchase all of Founder s 18.4 million shares at $4.17 per share IRVING, TX

Biote Announces Definitive Settlement with Founder

Company to repurchase all of Founder s 18.4 million shares at $4.17 per share

IRVING, TX April 29, 2024 biote Corp. (NASDAQ: BTMD) ( Biote or the Company ), a leading solutions provider in

preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced it has entered into a definitive settlement agreement (the Settlement Agreement ) that concludes outstanding

litigation with Dr. Gary S. Donovitz ( Donovitz ), founder and stockholder of Biote.

The Settlement Agreement includes a mutual

release of all claims relating to litigation between Donovitz and Biote; the termination of the founder advisory agreement by and between Donovitz and BioTE Medical, LLC; two year non-compete and non-solicitation agreements for Donovitz; and a voting agreement with customary terms acceptable to the Company. Additionally, Biote will repurchase all 18.4 million Biote shares beneficially held by Donovitz.

Terry Weber, Biote Chief Executive Officer, commented, We are pleased to conclude this legal matter, which resolves prolonged and costly

litigation. Backed by our strong capital position and cash generation capability, we are well positioned to execute on this multi-year share repurchase that we believe will be accretive to shareholder value. With this legal matter behind us, we are

fully focused on advancing our strategic objectives and continuing to drive profitable growth.

Under the terms of the Settlement Agreement, Biote

will repurchase all of Donovitz s Biote Class A common units of BioTE Holdings, LLC ( Holdings Units ), shares of Class V common stock of the Company ( Class V Shares and, together with the Holdings Units,

Paired Interests ) and shares of Class A common stock of the Company ( Class A Shares ) for approximately $76.9 million in the aggregate. The average price for repurchased Class A Shares, Holdings Units and

Class V shares will be $4.17 per share and will occur over the following three-year schedule:

The Company plans to provide additional details concerning the anticipated financial impacts of the

settlement when it reports first quarter financial results on Tuesday, May 7, 2024, after the close of the market.

Biote is transforming healthy aging through innovative, personalized hormone optimization and therapeutic wellness solutions delivered by Biote-certified

medical providers. Biote trains practitioners to identify and treat early indicators of aging conditions, an underserved global market, providing affordable symptom relief for patients and driving clinic success for practitioners.

Forward-Looking Statements

This press release contains

certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Some of the forward-looking statements can be identified by

the use of forward-looking words. Statements that are not historical in nature, including the words may, can, should, will, estimate, plan, project,

forecast, intend, expect, hope, anticipate, believe, seek, target, continue, could, might, ongoing,

potential, predict, would and other similar expressions, are intended to identify forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that

are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual results or developments to differ materially from those expressed or implied by such forward-looking

statements, including but not limited to: the success of our dietary supplements to attain significant market acceptance among clinics, practitioners and their patients; our customers reliance on certain third parties to support the

manufacturing of bio-identical hormones for prescribers; our and our customers sensitivity to regulatory, economic, environmental and competitive conditions in certain geographic regions; our ability to

increase the use by practitioners and clinics of the Biote Method at the rate that we anticipate or at all; our ability to grow our business; the significant competition we face in our industry; the impact of strategic acquisitions and the

implementation of our growth strategies; our limited operating history; our ability to protect our intellectual property; the heavy regulatory oversight in our industry; changes in applicable laws or regulations; the inability to profitably expand

in existing markets and into new markets; the possibility that we may be adversely impacted by other economic, business and/or competitive factors, including recent bank failures; and future exchange and interest rates. The foregoing list of factors

is not exhaustive. You should carefully consider the foregoing factors and other risks and uncertainties described in the Risk Factors section of Biote s Annual Report on Form 10-K for the

fiscal year ended December 31, 2023 and other documents filed by Biote from time to time with the Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and

results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Biote assumes

no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Biote does not give any assurance that it will achieve its expectations.